Metastatic adrenocortical carcinoma treated with sunitinib: A case report

24Citations
Citations of this article
10Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Adrenocortical carcinoma (ACC) is a rare malignancy with poor prognosis. Palliative chemotherapy can be considered in patients with metastatic disease. Although mitotane- or cisplatin-based chemotherapy regimens are widely used, the effects of these agents have been limited. We have experienced a case that showed a partial response with sunitinib after failure of mitotane-based cytotoxic chemotherapy. The clinical benefit from sunitinib persisted 7.5 months in this case. To our knowledge, this is the first reported case showing the effects of sunitinib on metastatic ACC. © The Author (2009). Published by Oxford University Press. All rights reserved.

Cite

CITATION STYLE

APA

Lee, J. O., Lee, K. W., Kim, C. J., Kim, Y. J., Lee, H. E., Kim, H., … Lee, J. S. (2009). Metastatic adrenocortical carcinoma treated with sunitinib: A case report. Japanese Journal of Clinical Oncology, 39(3), 183–185. https://doi.org/10.1093/jjco/hyn146

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free